Back

The beneficial role of cardioprotective drugs in preventing cardiotoxicity in HER2 positive breast cancer, an echocardiographic point-of-view

22 May 2023 (14:00 - 15:00)
Organised by: Logo
Congress Presentation Part of: ePosters in cardiovascular disease in special populations 2 Cardio-Oncology HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Catia Oliveira

Sao Joao Hospital, Porto (Portugal)

6 More presentations in this session

Presentation thumbnail
A right ventricular function study in a group of breast cancer patients undergoing chemotherapy
Doctor M. Castro (Guimaraes, PT)
Abstract Slides
Presentation thumbnail
Baseline cardiovascular comorbidities in patients with hematological malignancies who receive cardiotoxoc treatment and possible cardiotoxic effects-the experience of our hospital
Doctor M. Stratinaki (Heraklion, GR)
Abstract Slides
Presentation thumbnail
Association between beta-1-blockers and reduced efficacy of pembrolizumab in non-small cell lung cancer
Doctor M. Laufer-Perl (Tel Aviv, IL)
Abstract Slides
Presentation thumbnail
Diastolic dysfunction is associated with development of heart failure in patients with breast cancer under chemotherapy
Doctor M. Castro (Guimaraes, PT)
Abstract Slides
Presentation thumbnail
Cardiotoxicity assessment according to current cardio-cncology guidelines in a population of female breast cancer patients
Doctor C. Oliveira (Porto, PT)
Abstract Slides

Access the full session

Session thumbnail
ePosters in cardiovascular disease in special populations 2

The Event

Event poster

Heart Failure 2023

22 May 2023 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Cardioprotective effects of prophylactic ACE Inhibitors in anthracycline-based chemotherapy: a systematic review and meta-analysis
thumbnail
Congress Presentation
Stop cardiotoxicity: the role of statin therapy in anthracycline treated patients
thumbnail
Congress Presentation
Cardiovascular toxicity surveillance in metastatic breast cancer patients receiving long-term HER2-targeted therapy: a retrospective multicentre study

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources